These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21199179)

  • 1. LRRK2 as a therapeutic target in Parkinson's disease.
    Tan EK; Schapira AH
    Eur J Neurol; 2011 Apr; 18(4):545-6. PubMed ID: 21199179
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.
    Estrada AA; Sweeney ZK
    J Med Chem; 2015 Sep; 58(17):6733-46. PubMed ID: 25915084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of LRRK2-associated Parkinson's disease in central Norway.
    Aasly JO; Toft M; Fernandez-Mata I; Kachergus J; Hulihan M; White LR; Farrer M
    Ann Neurol; 2005 May; 57(5):762-5. PubMed ID: 15852371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
    Lee BD; Dawson VL; Dawson TM
    Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.
    Tomiyama H; Li Y; Funayama M; Hasegawa K; Yoshino H; Kubo S; Sato K; Hattori T; Lu CS; Inzelberg R; Djaldetti R; Melamed E; Amouri R; Gouider-Khouja N; Hentati F; Hatano Y; Wang M; Imamichi Y; Mizoguchi K; Miyajima H; Obata F; Toda T; Farrer MJ; Mizuno Y; Hattori N
    Mov Disord; 2006 Aug; 21(8):1102-8. PubMed ID: 16622854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.
    West AB
    Mov Disord; 2015 Feb; 30(2):180-9. PubMed ID: 25448543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease.
    Infante J; Rodríguez E; Combarros O; Mateo I; Fontalba A; Pascual J; Oterino A; Polo JM; Leno C; Berciano J
    Neurosci Lett; 2006 Mar; 395(3):224-6. PubMed ID: 16298482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?
    Taymans JM; Greggio E
    Curr Neuropharmacol; 2016; 14(3):214-25. PubMed ID: 26517051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics.
    Bonifati V
    Eur J Hum Genet; 2006 Oct; 14(10):1061-2. PubMed ID: 16835587
    [No Abstract]   [Full Text] [Related]  

  • 13. [Genetics and present therapy options in Parkinson's disease: a review].
    Bereznai B; Molnar MJ
    Ideggyogy Sz; 2009 May; 62(5-6):155-63. PubMed ID: 19579663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2.
    Doggrell SA
    Expert Opin Investig Drugs; 2011 Apr; 20(4):587-90. PubMed ID: 21314482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.
    Elbaz A
    Lancet Neurol; 2008 Jul; 7(7):562-4. PubMed ID: 18539536
    [No Abstract]   [Full Text] [Related]  

  • 16. The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease.
    Li C; Ting Z; Qin X; Ying W; Li B; Guo Qiang L; Jian Fang M; Jing Z; Jian Qing D; Sheng Di C
    Mov Disord; 2007 Dec; 22(16):2439-43. PubMed ID: 17960808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Sanjari Moghaddam H; Aarabi MH
    Mov Disord; 2018 Dec; 33(12):1876. PubMed ID: 30452792
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: The G2019S LRRK2 mutation is uncommon amongst Greek patients with familial Parkinson's disease.
    Papapetropoulos S; Argyriou AA; Mitsi G; Chroni E
    Eur J Neurol; 2007 Nov; 14(11):e6. PubMed ID: 17956439
    [No Abstract]   [Full Text] [Related]  

  • 19. A study of LRRK2 mutations and Parkinson's disease in Brazil.
    Pimentel MM; Moura KC; Abdalla CB; Pereira JS; de Rosso AL; Nicaretta DH; Campos M; de Almeida RM; dos Santos JM; Bastos IC; Mendes MF; Maultasch H; Costa FH; Werneck AL; Santos-Rebouças CB
    Neurosci Lett; 2008 Mar; 433(1):17-21. PubMed ID: 18201824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mutation in LRRK2 is associated with familial presentation of Parkinson's disease in a Chilean kindred].
    Miranda M
    Rev Med Chil; 2007 Mar; 135(3):406-7. PubMed ID: 17505590
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.